- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04825080
Carotid Asymptomatic Stenosis (CARAS)
Natural History of Asymptomatic Carotid Artery Stenosis in the Modern Era
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Primary end point is to evaluate the rate of cerebral ischemic events (stroke or transient ischemic attack) in patients with asymptomatic carotid artery stenosis > 60% (Nascet criteria) in a 5-year follow-up period. It is a prospective observational study conducted on patients enrolled from January 2019 to March 2020 and with the end of follow-up scheduled in 2025.
The medical therapy recommended includes antihypertensive drugs to maintain good blood pressure control, statin therapy and antiplatelet administration.
Secondary end points are the evaluation of plaque progression, the identification of comorbidities or plaque characteristics associated with a higher risk for cerebral ischemic events and the patient adherence to the best medical therapy in a real world scenario. The global survival and the factors influencing survival will be investigated as well.
Separate analyses are performed for patients with total carotid occlusion or carotid artery re-stenosis.
Patient's cohort: with the hypothesis of 3 neurologic (transient ischemic attack or stroke) events per 100 patients/year during a 5 years follow-up period and consequently a number of 40-50 events (primary outcome), the study cohort with a native asymptomatic carotid artery stenosis will include at least 300 patients. Patients with carotid occlusion or restenosis are evaluated separately for a secondary analysis only.
Patients are prospectively identified and enrolled in a single center vascular surgery ambulatory and a duplex ultrasonography (DUS) laboratory. Carotid artery stenosis are identified and the degree of stenosis >60% (NASCET criteria) is evaluated according to the current guidelines for stenosis identification through blood flow velocities. Patients enrollment goes from January 2019 to March 2020. The investigators prospectively complete the dedicated database including clinical characteristics, cardiovascular risk factors, medical therapy in use, features of the carotid plaque and contralateral carotid status.
Clinical characteristics included in the database: age, sex, hypertension (systolic blood pressure ≥140 or/and diastolic ≥90 mmHg, or specific therapy), dyslipidemia (total cholesterol ≥200 mg/dl or low density lipoprotein ≥120 mg/dl or specific therapy), diabetes mellitus (pre-diagnosed, in therapy with oral hypoglycemic drugs or insulin), current smoking, coronary artery disease (defined as a history of angina pectoris, myocardial infarction or coronary revascularization), chronic obstructive pulmonary disease (defined as chronic bronchitis or emphysema), chronic kidney disease (glomerular filtration rate <60 ml/min), contralateral carotid occlusion, stenosis and atrial fibrillation (paroxysmal or permanent).
Medical therapy: antiplatelet types, anticoagulant therapy, statin therapy, anti hypertensive medical therapy.
Carotid plaque characteristics for the analysis: degree of stenosis (flow measurement analysis), plaque ulcerations and echoluncency.
The follow-up consists of a telephone interview any six months and an annual clinical and duplex examination until a 5-years follow-up is reached or the patient withdraws from the study.
Patients that will be enrolled will sign specific consents. Sensitive patient information will not be available during data analysis. The clinical study will be carried out according to the ethical principles of the Declaration of Helsinki and following the active regulations on observational studies.
Patients who underwent a transient ischemic attach or a stroke within the 6-months before the enrollment are excluded from the study. Any neurological symptom occurred during the follow-up needs to be certified by an in hospital neurologist physical examination.
Statistical analysis: Continuous variables were described with mean and standard deviation. Continuous variables were compared by unpaired Student' t test in case of normal distribution, otherwise by Mann-Whitney's test. The differences between percentages were assessed using Fisher's test or Chi-square test, when appropriate. Univariate analysis will be performed by Kaplan Meier analysis (log-rank test) and single factor Cox analysis . Multivariate analyses with Cox analysis will be performed including factors considered statistical significant (P value ≤ .05) at the univariate analyses. Risk factors were reported as hazard ratio (HR) and 95% of confidence interval (CI). A value of p ≤ .05 (two-tailed) was considered to be significant. The statistical tests were performed using SPSS® 21.0 for Windows® (SPSS, Chicago, Il, USA).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Bologna, Italy, 40138
- Policlinico S. Orsola Malpighi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- asymptomatic carotid artery stenosis (according to the ESVS guidelines) >60% (NASCET criteria) with a physical examination and a DUS at the S. Orsola Malpighi hospital from 2019 to 2025.
Exclusion Criteria:
- Patients submitted to carotid revascularization will be included until the revascularization.
- Patients who underwent a transient ischemic attach or a stroke within the 6-months before the enrollment are excluded from the study
- Restenosis
- Carotid total occlusion
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebral ischemic events
Time Frame: 5 years
|
Stroke and transient cerebral ischemic events or amaurosis fugax, evaluated by clinical neurologist by clinical examination (National Institutes of Health Stroke Scale, NIHSS or modified Rankin scale, mRS)
|
5 years
|
Ipsilateral cerebral ischemic events
Time Frame: 5 years
|
Ipsilateral stroke and transient cerebral ischemic events or amaurosis fugax, evaluated by clinical neurologist by clinical examination (National Institutes of Health Stroke Scale, NIHSS or modified Rankin scale, mRS)
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plaque progression
Time Frame: 5 years
|
Increasing of carotid stenosis from 60%-79% to >80% according with duplex ultrasound flow measurement (Nascent criteria)
|
5 years
|
Patient's adherence to the medical therapy
Time Frame: 5 years
|
adherence to medical drugs prescribed
|
5 years
|
Survival
Time Frame: 5 years
|
Survival rate
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STECA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asymptomatic Carotid Artery Stenosis
-
Heinrich-Heine University, DuesseldorfRecruitingCarotid Artery Plaque | Carotid Artery Diseases | Carotid Artery Stenosis Asymptomatic | Carotid Artery StenosisGermany
-
Xuanwu Hospital, BeijingChanghai Hospital; Peking Union Medical College Hospital; The Second Hospital... and other collaboratorsRecruitingCarotid Artery Stenting | Carotid Endarterectomy | Best Medical Treatment | Carotid Artery Stenosis AsymptomaticChina
-
Centre Hospitalier St AnneHôpitaux Universitaires Paris Ile-de-Franc OuestNot yet recruiting
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center and other collaboratorsRecruitingCarotid Atherosclerosis | Asymptomatic Carotid Artery Stenosis | Carotid Artery AtheromaUnited States
-
Vienna General HospitalCompletedAsymptomatic | ArteryAustria
-
Canadian Medical and Surgical Knowledge Translation...AmgenRecruitingCarotid Artery Stenosis | Asymptomatic Carotid Artery StenosisCanada
-
Ochsner Health SystemWithdrawnTCD | Symptomatic Carotid Stenosis | Asymptomatic Carotid Stenosis | HITSUnited States
-
Albert Einstein Healthcare NetworkTerminatedCarotid Stenosis | Femoral Arterial Stenosis | Carotid Bruit Asymptomatic | Carotid MurmurUnited States
-
Meshalkin Research Institute of Pathology of CirculationFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical... and other collaboratorsRecruitingPatients With Aterosclerotic Carotid Stenosis | Symptomatic Patients (Stenosis > 50%) | Asymptomatic Patients (Stenosis ≥80%)Russian Federation
-
Meshalkin Research Institute of Pathology of CirculationCompletedPatients With Aterosclerotic Carotid Stenosis | Symptomatic Patients (Stenosis > 50%) | Asymptomatic Patients (Stenosis ≥80%)Russian Federation
Clinical Trials on duplex ultrasound and computed tomography angiography
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedCOVID-19 | Critical Illness | Venous Thromboembolism | SARS-CoV Infection | Pulmonary Embolism | Sars-CoV2 | Venous Thromboses | Pulmonary Embolism and Thrombosis | Venous Thromboses, Deep | Venous Thrombosis PulmonarySpain
-
Centre Hospitalier Universitaire de NiceCompletedEndovascular Repair of Abdominal Aortic AneurysmFrance
-
Asan Medical CenterBoston Scientific CorporationActive, not recruitingCoronary Artery DiseaseKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedCoronary Artery Disease | Aortic Valve Disease | Computed Tomography Angiography | Coronary AngriographyNetherlands
-
Rijnstate HospitalCompletedPeripheral Arterial DiseaseNetherlands
-
Universitätsklinikum Hamburg-EppendorfSiemens Healthcare Diagnostics IncNot yet recruitingCoronary Artery Disease | Acute Ischemic Stroke
-
University Hospital Inselspital, BerneStanley Thomas Johnson Foundation, Bern, SwitzerlandCompletedEmbolism, PulmonarySwitzerland
-
Seoul National University Bundang HospitalCompletedDiabetes Mellitus | Coronary AtherosclerosisKorea, Republic of
-
Clinical Research Office Imaging DivisionCompletedAortic Aneurysm, AbdominalNetherlands
-
University of EdinburghNHS Lothian; NHS Greater Glasgow and Clyde; University of Glasgow; Chief Scientist...RecruitingCardiovascular Diseases | Kidney Transplant; ComplicationsUnited Kingdom